Literature DB >> 14576201

Novel polypyrimidine variation (IVS46: del T -39...-46) in ABCA1 causes exon skipping and contributes to HDL cholesterol deficiency in a family with premature coronary disease.

Seung Ho Hong1, Jeffrey Rhyne, Michael Miller.   

Abstract

Recent studies have implicated mutations in the ATP-binding cassette transporter A1, ABCA1, as a cause of Tangier disease (TD) and familial hypoalphalipoproteinemia (FHA). We investigated a proband with very low levels of high-density lipoprotein cholesterol (HDL-C, 6 mg/dL) and a history of premature coronary heart disease (CHD). Sequencing of the ABCA1 gene revealed 2 distinct variants. The first mutation was a G5947A substitution (R1851Q). The second mutation was a single-nucleotide deletion of thymidine in a polypyrimidine tract located 33 to 46 bps upstream to the start of exon 47. This mutation does not involve the 3' acceptor splice site and is outside the lariat branchpoint sequence (IVS46: del T -39...-46). Amplification of cDNA obtained in cultured fibroblasts of the proband and affected family member revealed an abnormally spliced cDNA sequence with skipping of exon 47. These variants were not identified in over 400 chromosomes of healthy whites. Compound heterozygotes (n=4) exhibited the lowest HDL-C (11+/-5 mg/dL) and ApoA-I (35+/-15 mg/dL) compared with wild-type (n=25) (HDL-C 51+/-14 mg/dL; ApoA-I 133+/-21 mg/dL) (P<0.0005) or subjects affected with either R1851Q (n=6) (HDL-C 36+/-8; ApoA-I 117+/-19) or IVS46: del T -39...-46 (n=5) (HDL-C 31+9; ApoA-I 115+28 (P<0.01). These data suggest that polypyrimidine tract variation may represent a novel mechanism for altered splicing and exon skipping that is independent of traditional intronic variants as previously identified in acceptor/donor splice regions or the lariat branchpoint domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576201     DOI: 10.1161/01.RES.0000102957.84247.8F

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Significance of Cholesterol-Binding Motifs in ABCA1, ABCG1, and SR-B1 Structure.

Authors:  Alexander D Dergunov; Eugeny V Savushkin; Liudmila V Dergunova; Dmitry Y Litvinov
Journal:  J Membr Biol       Date:  2018-12-06       Impact factor: 1.843

2.  Do mutations causing low HDL-C promote increased carotid intima-media thickness?

Authors:  Michael Miller; Jeffrey Rhyne; Seung Ho Hong; Gina Friel; Christina Dolinar; Ward Riley
Journal:  Clin Chim Acta       Date:  2006-10-07       Impact factor: 3.786

3.  APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome.

Authors:  Michael Miller; Jeffrey Rhyne; Hegang Chen; Valerie Beach; Richard Ericson; Kalpana Luthra; Manjari Dwivedi; Anoop Misra
Journal:  Arch Med Res       Date:  2007-03-26       Impact factor: 2.235

4.  A common variant in combination with a nonsense mutation in a member of the thioredoxin family causes primary ciliary dyskinesia.

Authors:  Bénédicte Duriez; Philippe Duquesnoy; Estelle Escudier; Anne-Marie Bridoux; Denise Escalier; Isabelle Rayet; Elisabeth Marcos; Anne-Marie Vojtek; Jean-François Bercher; Serge Amselem
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Allele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolism.

Authors:  Alicia D Howard; Xiaochun Wang; Megana Prasad; Avinash Das Sahu; Radhouane Aniba; Michael Miller; Sridhar Hannenhalli; Yen-Pei Christy Chang
Journal:  PLoS One       Date:  2019-04-30       Impact factor: 3.240

6.  Multiple splice defects in ABCA1 cause low HDL-C in a family with hypoalphalipoproteinemia and premature coronary disease.

Authors:  Jeffrey Rhyne; Myrna M Mantaring; David F Gardner; Michael Miller
Journal:  BMC Med Genet       Date:  2009-01-08       Impact factor: 2.103

7.  The effect of ABCA1 gene polymorphisms on ischaemic stroke risk and relationship with lipid profile.

Authors:  Alireza Pasdar; Ghasem Yadegarfar; Alastair Cumming; Lawrence Whalley; David St Clair; Mary-Joan MacLeod
Journal:  BMC Med Genet       Date:  2007-06-06       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.